VEGFR + TPC

VEGFR + TPC appears to refer to a combination therapy involving a vascular endothelial growth factor receptor (VEGFR) inhibitor and a tumor-penetrating conjugate (TPC), likely in the form of a peptide-drug conjugate. VEGFR inhibitors block the activity of VEGF receptors, which are key regulators of angiogenesis—the formation of new blood vessels—thereby inhibiting tumor growth by reducing blood supply to tumors[1][3][5]. Tumor-penetrating conjugates (TPCs), such as lytic peptides or other cytotoxic agents linked to targeting moieties, are designed to enhance drug delivery specifically into tumor tissue, often by disrupting cell membranes or exploiting specific tumor microenvironment features[3]. The combination aims for dual action: antiangiogenic effects via VEGFR inhibition and direct cytotoxicity through the TPC component. This approach is under investigation for cancer therapy, particularly in settings like hepatocellular carcinoma where targeted delivery can improve efficacy and reduce systemic toxicity[3].